piwik-script

Intern
    Onkologische Forschung

    AG Bargou

    Ralf C. Bargou: Chair for Translational Oncology

    Summary

    Our group is interested in the development of targeted and personalized therapies for patients with tumors of the lympho-hematopoietic system. We focus on characterization of oncogenic signaling networks in multiple myeloma and their underlying genetic aberrations in a combined functional and genetic approach Complementary to this, we develop T cell engaging therapies for cancer treatment in a variety of cancer entities. Our group translates the knowledge from preclinical research in these fields into the clinic and has initiated a broad early clinical trial program ranging from leukemia to prostate cancer. The program is supported by the central CCC MF Trial Office and is conducted in the Early Clinical Trials Unit (ECTU) of the CCC MF.
     

    Recent Publications

    Leich E, Schreder M, Pischimarov J, Stühmer T, Steinbrunn T, Rudelius M, Brünnert D, Chatterjee M, Langer C,  Keppler S, Heredia-Guerrero SC, Einsele H, Knop S, *Bargou RC, *Rosenwald A.. Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma. Blood Cancer Journal, 2021 Mar 4;11(3):51. doi: 10.1038/s41408-021-00442-2* equally contributing senior author.

    Wermke M, Kraus S, Ehninger A, Bargou R, Göbeler ME, Middeke JM, Koedam J, Pehl M, Bornhäuser M, Einsele H, Ehninger G, Cartellieri M Proof-of-concept for Rapidly Switchable Universal CAR-T Platform (UniCAR) in Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2021 Jun 3;137(22):3145-3148.

    Hummel  HD, Kufer P, Grüllich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, Goebeler ME, Miller K, De Santis  M, Loidl W, Dittrich C, Buck A, Lapa C,  Thurner A, Wittemer-Rump  S, Koca G, Boix O, Döcke WD, Finnern R, Kusi H, Ajavon-Hartmann A, Stienen S, Sayehli CM, Bülent P, and Bargou RC. Pasotuxizumab, a BiTE® Immune Therapy for Castration-Resistant Prostate Cancer: Phase 1, Dose-Escalation Study Findings. Immunotherapy, 2021 Feb;13(2):125-141.

    Klinger M, Zugmaier G, Nägele V, Goebeler M, Brandl C, Stelljes M, Lassmann H, von Stackelberg A, Bargou RC*, Kufer P*. Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events. Cancer Res. 2020 Jan 1;80(1):91-101.* equally contributing senior author.

    Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Gerhard Zugmaier, Nagorsen D, Bargou RC. Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia. Blood, 2018, 131(14):1522-1531.